Edgestream Partners L.P. acquired a new position in shares of Shire PLC (NASDAQ:SHPG) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 2,203 shares of the biopharmaceutical company’s stock, valued at approximately $364,000.
A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in Shire PLC by 0.9% during the 1st quarter. Vanguard Group Inc. now owns 1,542,634 shares of the biopharmaceutical company’s stock worth $268,773,000 after buying an additional 13,665 shares during the last quarter. BlackRock Inc. grew its stake in shares of Shire PLC by 4,217.7% in the first quarter. BlackRock Inc. now owns 1,433,475 shares of the biopharmaceutical company’s stock worth $249,755,000 after purchasing an additional 1,400,275 shares in the last quarter. Janus Capital Management LLC grew its stake in shares of Shire PLC by 10.7% in the first quarter. Janus Capital Management LLC now owns 1,365,226 shares of the biopharmaceutical company’s stock worth $237,854,000 after purchasing an additional 132,446 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Shire PLC by 19.7% in the first quarter. Bank of America Corp DE now owns 1,326,114 shares of the biopharmaceutical company’s stock worth $231,049,000 after purchasing an additional 218,291 shares in the last quarter. Finally, Glenview Capital Management LLC bought a new position in shares of Shire PLC in the first quarter worth $176,927,000. Hedge funds and other institutional investors own 19.13% of the company’s stock.
Shire PLC (NASDAQ SHPG) traded up 1.612% during trading on Friday, hitting $160.375. The company had a trading volume of 1,671,147 shares. The stock has a 50-day moving average of $153.73 and a 200 day moving average of $168.99. Shire PLC has a one year low of $139.36 and a one year high of $209.22. The company has a market capitalization of $47.77 billion, a price-to-earnings ratio of 71.756 and a beta of 1.61.
Shire PLC (NASDAQ:SHPG) last released its earnings results on Friday, October 27th. The biopharmaceutical company reported $3.37 earnings per share for the quarter, missing the consensus estimate of $3.66 by ($0.29). Shire PLC had a return on equity of 14.10% and a net margin of 4.70%. Equities analysts forecast that Shire PLC will post $14.93 EPS for the current fiscal year.
The firm also recently announced a semiannual dividend, which will be paid on Friday, October 20th. Shareholders of record on Friday, September 8th will be paid a dividend of $0.1527 per share. This represents a yield of 0.21%. The ex-dividend date of this dividend is Thursday, September 7th. Shire PLC’s payout ratio is presently 41.07%.
SHPG has been the subject of several research analyst reports. Royal Bank Of Canada set a $221.00 price objective on Shire PLC and gave the company a “buy” rating in a report on Thursday, May 18th. HSBC Holdings plc lowered Shire PLC from a “hold” rating to a “reduce” rating in a report on Friday, May 19th. Sanford C. Bernstein lowered Shire PLC from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $209.22 to $161.09 in a report on Thursday, May 25th. BidaskClub raised Shire PLC from a “strong sell” rating to a “sell” rating in a report on Friday, June 23rd. Finally, ValuEngine downgraded Shire PLC from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and fourteen have assigned a buy rating to the stock. Shire PLC presently has an average rating of “Buy” and a consensus price target of $220.08.
ILLEGAL ACTIVITY NOTICE: This story was reported by BBNS and is the property of of BBNS. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://baseballnewssource.com/markets/2203-shares-in-shire-plc-shpg-purchased-by-edgestream-partners-l-p/1601879.html.
Shire PLC Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with our FREE daily email newsletter.